When Curtain Falls: 4+7 To 4+N Signals End To Branded Generics In China?
After only two multinationals managed to win bids in China's massive new centralized drug procurement scheme, other foreign firms were hoping to get a break in the second round. But this may not materialize.
You may also be interested in...
China’s massive centralized "4+7" drug procurement scheme is now being rolled out nationwide, involving some of the largest provincial markets and huge product volumes.
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.